Company: BDRX
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001214659-25-016821
Chunk: 155

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: F-1
Chunk 155
---
MA) received by it in connection with the issue or sale of the securities in circumstances in which Section 21(1) of the FSMA 
 does not apply to us; and                                                                                                                 |

| ● | it has complied and will comply with all applicable provisions of the FSMA with respect to anything done 
 by it in relation to the securities in, from or otherwise involving the United Kingdom.                  |

| 90 |

Switzerland.
The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the SIX) or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for
issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses
under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland.
Neither this document nor any other offering or marketing material relating to the securities or the offering may be publicly distributed
or otherwise made publicly available in Switzerland.

Neither this document nor
any other offering or marketing material relating to the offering, or the securities have been or will be filed with or approved by any
Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by,
the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be authorized under the
Swiss Federal Act on Collective Investment Schemes (CISA). Accordingly, no public distribution, offering or advertising, as defined in
CISA, its implementing ordinances and notices, and no distribution to any non-qualified investor, as defined in CISA, its implementing
ordinances and notices, shall be undertaken in or from Switzerland, and the investor protection afforded to acquirers of interests in
collective investment schemes under CISA does not extend to acquirers of securities.

Australia. No
placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities
and Investments Commission (ASIC), in relation to the offering.

This prospectus does not constitute
a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the Corporations Act) and does
not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the
Corporations Act